Such metabolic interdependencies highlight the imperative for dual targeting of tumor-stromal axes, exemplified by ongoing trials combining glutaminase inhibitors (telaglenastat) with PD-L1 blockade in OXPHOS-high malignancies [20, 70]. Here, GLS is linked to neoplasm.